Clinical Evidence on GLP-1 Receptor Agonists and Mental Health
Glucagon-like peptide-1 receptor agonists mental health effects were studied using genetic methods to assess their impact on psychiatric conditions. Evidence suggests these drugs may influence risk for schizophrenia and substance use disorders.…
Review of Cannabinoid Clinical Trials in Mental Health and Substance Use Treatment
Cannabinoid clinical trials mental health substance use treatment research remains limited and inconclusive. Current randomized controlled trials have not firmly established cannabinoids as effective or safe primary treatments. Clinicians should…
Adverse Childhood Experiences and Substance Use Disorders: What a Kenyan Hospital Study Shows
Adverse childhood experiences in addiction treatment are highly prevalent among adults in a Kenyan psychiatric hospital. This study found strong associations between specific childhood adversities and current substance use patterns. Understanding these…
Insights on Cannabinoid Clinical Trials for Mental Health and Substance Use
Cannabinoid clinical trials mental health substance use provide evidence on the efficacy and safety of cannabinoids in treating these disorders. This meta-analysis reviews randomized controlled trials assessing cannabinoids as primary treatments. The…
Cannabinoid Clinical Trials: Mental Health & Substance Use
Cannabinoids mental health studies highlight that current evidence does not firmly establish cannabinoids as effective primary treatments for most mental health or substance use disorders. Adverse effects were commonly reported, emphasizing clinical…
Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis
This study examines the cannabis use disorder psychiatric risk profile compared to other substance use disorders. Findings indicate lower rates of schizophrenia, depression, and psychotic disorders in cannabis users. These insights inform clinical risk…
Governor Signs Bill to Launch Ibogaine Clinical Trials – Magnolia Tribune
Ibogaine clinical trials legislation marks a significant step in addiction treatment research. This bill enables formal studies to evaluate ibogaine's efficacy and safety. It opens regulatory pathways for controlled psychedelic clinical trials.
Understanding Genetic Nurture in Substance Use Transmission
This research highlights genetic nurture substance use, showing how parental genetics and environment influence offspring risk. It reveals dual pathways of inheritance and environment in substance use disorders. Clinicians can better assess family risk…
Review of Cannabinoid Clinical Trials for Mental Health Treatment
This cannabinoid clinical trials mental health treatment review summarizes current evidence on cannabinoids' efficacy and safety for mental health disorders. The review highlights consistent adverse effects reported in trials. Careful clinical monitoring…
Why People Use Cannabis Predicts Whether Use Becomes Harmful, Review Finds
A 2024 narrative review highlights that cannabis use motives, particularly coping motives, strongly predict cannabis-related problems and disorder. Medical and coping motives overlap, complicating clinical assessment. Understanding cannabis use motives…